TNB-383B *

 

TNB-383B is a BCMA x CD3 T-cell engaging bispecifc antibody being studied in relapsed or refractory multiple myeloma who have received at least 3 prior lines of therapy.

TNB-383B is being developed by TeneoOne through Phase 1. AbbVie holds the exclusive right to acquire TeneoOne and lead subsequent global development and commercialization of TNB-383B.

 

Type of Molecule

Biologic

Target

CD3-BCMA

Product Type

New Indication
Potential Indication Region Phase (1, 2, 3, Submitted, Approved)
Multiple Myeloma (MM) n/a
Phase 1